Assembly Biosciences Inc.

News & Events

Press Releases

In The Media

1. Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

   GlobeNewswire MAY 8, 2025 4:05 PM EDT
   – Ongoing clinical studies for four candidates on track with data expected in 2025, includ...
   READ ARTICLE

2. New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

   GlobeNewswire MAY 7, 2025 8:00 AM EDT
   – Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a wi...
   READ ARTICLE

3. Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

   GlobeNewswire APR 9, 2025 2:00 AM EDT
   – Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a...
   READ ARTICLE

4. Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

   GlobeNewswire MAR 20, 2025 4:05 PM EDT
   – Four development candidates in clinical studies with data anticipated this year, con...
   READ ARTICLE

5. Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

   GlobeNewswire FEB 26, 2025 8:00 AM EST
   – Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy ...
   READ ARTICLE

6. Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

   GlobeNewswire FEB 20, 2025 8:00 AM EST
   – ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposu...
   READ ARTICLE

7. Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

   GlobeNewswire DEC 26, 2024 8:00 AM EST
   – ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting onc...
   READ ARTICLE

8. Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

   GlobeNewswire DEC 19, 2024 8:00 AM EST
   —Assembly Bio to receive approximately $20.1 million equity investment and $10 million in ...
   READ ARTICLE

9. Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

   GlobeNewswire NOV 7, 2024 4:05 PM EST
   Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibito...
   READ ARTICLE

10. Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

    GlobeNewswire SEP 23, 2024 8:00 AM EDT
    – ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of u...
    READ ARTICLE